Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of its senior leadership team will present at three upcoming investor conferences in September.

Conference Details:

Event: H.C. Wainwright 26^th Annual Global Investment Conference

Details: Presenting on Wednesday, September 11, 2024, at 11:30 a.m. ET and hosting investor meetings in New York, NY.

Event: Stifel Immunology and Inflammation Virtual Summit​

Details: Presenting on Tuesday, September 17, 2024, at 12:00 p.m. ET and hosting virtual investor meetings.

Event: Cantor Global Healthcare Conference

Details: Presenting on Tuesday, September 17, 2024, at 2:30 p.m. ET and hosting investor meetings in New York, NY.

Links for live webcasts and replays, if available, will be posted on the News & Events page in the Investors & Media section of the Zura Bio website. Presentations will be archived on the website for at least 30 days following the event.

ABOUT ZURA BIO

Zura Bio is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. Currently, Zura Bio is developing three assets which have completed Phase 1/1b studies and are Phase 2 ready. The company is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880), with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other novel indications with unmet needs.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240903983694/en/